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Introduction
Bone is continuously renewed by the process of remod-
eling in which "old bone" is removed from the surfaces
of trabecular and cortical bone by osteoclasts and subse-
quently replaced by a new bone laid down by
osteoblasts. Regulation of bone reconstruction process
was a mystery for many years. In early 1980s Rodan and
Martin postulated that osteoclasts formation and activity
are regulated by osteoblasts [1]. In 1990s osteoprote-
gerin/receptor activator of nuclear factor-κB and its lig-
and (OPG/RANK/ RANKL) signaling system was final-
ly identified. Currently, we know that this triad is essen-
tial not only for pathophysiology of bone remodeling but
is also involved in immune and vascular control systems.
Metabolic bone dysfunction in chronic kidney dis-
ease (CKD) is a result of vitamin D and parathyroid
system disorder. With the decline in glomerular filtra-
tion rate (GFR) and phosphate retention, hyperphos-
phatemia and impaired production of vitamin D occur.
It leads to decrease of serum ionized calcium concen-
tration. Decreased concentration of ionized calcium
and calcitriol together with hyperphosphatemia stimu-
late parathormon (PTH) secretion. Constant stimula-
tion of PTH secretion leads to hyperplasia of parathy-
roid glands and finally causes secondary hyper-
parathyroidism [2]. In end stage renal disease (ESRD)
a higher PTH concentrations are required to maintain
homeostasis of bone metabolism. 
In renal osteodystrophy (ROD) remodeling may be
up or down regulated which results in high (predomi-
nant hyperparathyroid bone disease and mixed uremic
osteodystrophy) or low (adynamic bone disease and
osteomalacia) turnover renal osteopathy. Correct ROD
diagnosis is crucial for adequate treatment. The only
way to distinguish unquestionably among different
types of ROD is bone biopsy which is invasive and
painful procedure. Therefore researches are looking
for noninvasive diagnostic methods and trying to use
biochemical markers of bone turnover.
Osteoprotegerin (OPG)
Osteoprotegerin, called "bone protector", belongs to
TNF receptor's family, is a soluble glycoprotein (has
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no transmembrane domain) consisting of 380
aminoacids and seven domains. It is expressed in
many types of cells like osteoblasts, heart, kidney,
liver, spleen and bone marrow [3]. In bone tissue OPG
is produced by osteoblasts, while in the vessels by
endothelial (EC) and vascular smooth muscle
(VSMCs) cells. 
Molecules that up regulate OPG synthesis by
osteoblasts are: IL-1α, IL-6, IL-11, IL-17, IL-18, 
TNF-α, TNF-ß, bone morphogenic protein (BMP-2),
calcium, vitamin D3, estrogens, angiotensin II and
platelet derived growth factor (PDGF) [4]. Next, PTH,
glucocorticoids, prostaglandin E2, immunosuppres-
sant drugs, peroxisome proliferators activated receptor
(PPAR-γ). and basic fibroblast growth factor (bFGF)
down regulate OPG production [4].
OPG has been identified as a cytokine that increas-
es the mineral density and volume of bone tissue by
decreasing the number of active osteoclasts. Over
expression of OPG in transgenic mice results in severe
osteopetrosis, characterized by increased bone turnover
and an inhibition of osteoclastogenesis [5]. OPG-defi-
cient mice develop osteoporosis because of an unop-
posed actions of RANKL to stimulate osteoclastic
cells formation, activity and survival  [6]. Based on the
presence of renal artery and aortic medial calcification
in osteoprotegerin deficient mice, OPG also appears to
protect large vessels from medial calcification [7].
Osteoprotegerin functionally acts as a decoy recep-
tor that blocks interaction between the receptor activa-
tor of nuclear factor-κB (RANK) and its ligand
(RANKL), thereby inhibits osteoclasts' differentiation
as well as theirs activity and prevents bone loss. OPG
has also been shown to bind TNF-related apoptosis
inducing ligand (TRAIL/Apo2L) – another member of
TNF ligand super family. In this way it inhibits the
induction of human osteoclasts apoptosis by prevent-
ing TRAIL from binding to its receptors [8,9]. OPG is
also involved in efficient antibody response and B-cell
maturation [10].
In endothelial cells OPG is physically associated
with von Willebrand factor (vWF), glycoprotein
involved in primary hemostasis and also important
marker of endothelial injury. In response to inflamma-
tory stimuli OPG and vWF are  rapidly secreted that
can proof OPG role in vascular injury, inflammation
and hemostasis [11]. Because OPG is able to bind vWF
reductase, thrombospondin-1 (TSP-1), it may also play
a role in regulation of thrombus formation [11].
Receptor activator of nuclear factor-κB
(RANK)
RANK, another member of TNF receptor superfamily,
is a homotrimeric transmembrane protein consisting of
616 aminoacids. It is expressed on osteoclasts' precur-
sors, mature osteoclasts, dendritic cells, mammary
glands, and some cancer cells including breast and
prostate cancers – tumors with very high bone metasta-
tic potential [3]. After binding its ligand – RANKL,
RANK assembles into functional trimeric receptor and
this trimerisation is required to generate multiple intra-
cellular signals that regulate cell differentiation, func-
tion and survival, among the others – mature and func-
tional osteoclasts.
Receptor activator of nuclear factor-κB ligand
(RANKL)
RANKL, similar to OPG, belongs to TNF super fami-
ly. It is a homotrimeric glycoprotein consisting of 316
aminoacids which exists as a transmembrane protein
and in soluble form. Most of the factors stimulated
osteoclasts' formation and activity induce RANKL
expression by osteoblastic and stromal cells. RANKL
is also expressed in activated T-lymphocytes, lymph
nodes, thymus, mammary glands, lungs, spleen and
bone marrow [3]. It is considered to be a dendritic-cell-
stimulation agent that was a reason for suggesting its
first name TRANCE – TNF-related activation-induced
cytokine. RANKL acts as a survival factor for dendrit-
ic cells and for mature T-cells through regulating their
proliferation [12].
While OPG presents as a soluble bone protector,
RANKL is considered to be stimulator of bone resorp-
tion. It is a pro-resorptive factor because of induction of
osteoclasts' differentiation and activation of mature
osteoclasts. In contrast  to OPG deficient mice, RANKL
transgenic mice exhibit a marked osteoporosis while
mice disrupted for RANKL are strongly osteopetrotic
with a total absence of mature osteoclasts [13].
RANKL production is stimulated by IL-1, IL-6, IL-
11, IL-17, TNF-α, vitamin D3, calcium, PTH, gluco-
corticoids, prostaglandin E2 and immunosuppressive
drugs. Its production is down regulated by TGF-ß [4].
RANKL stimulates RANK and in presence of stim-
ulating factors (e.g. M-CSF) may lead to initiation of
osteoclastogenesis – development of multinucleated
bone-resorptive osteoclasts from monocytes' precur-
sors. It also promotes the resorptive activity and sur-
vival of mature osteoclasts. RANKL is assumed to
stimulate osteogenic differentiation and calcification
of vascular smooth muscle cells as well [14].
OPG/RANK/RANKL interaction
RANKL acts through its receptor RANK. After binding,
RANKL induces intracellular signals that regulate dif-
ferentiation, function and survival of osteoclasts. OPG
secreted by osteoblastic lineage cells, acts as a decoy
receptor binding RANKL and preventing RANKL
interaction with RANK. This results in inhibition of 
200 K. Klejna et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(2): 200 (199-206) 
doi: 10.2478/v10042-009-0035-x
osteoclastic differentiation and in consequence inhibits
bone resorption. Additionally OPG modulate RANKL
half-life, and in turn, RANKL controls the bioavail-
ability of OPG, its internalization and degradation
[15]. Because OPG directly counter all RANKL-medi-
ated actions through RANK, RANKL/OPG ratio is an
important determinant of bone mass and skeleton
integrity. Imbalances in the RANKL/OPG ratio or
RANK signaling underlie the pathology of many
skeletal disorders with excessive bone loss, excessive
bone formation, or diseases with disordered bone
remodeling [16]. It also has been shown that this sys-
tem is involved in regulation of immune system and
development of vascular calcification [15].
OPG/RANK/RANKL role in pathogenesis 
of skeletal diseases 
Nowadays, many OPG/RANK/RANKL-mediated dis-
eases are known. Among others, there are metabolic
bone diseases, like postmenopausal osteoporosis due
to estrogen deficiency as well as sporadic Paget dis-
ease – both with enhanced RANKL expression and
increased RANK responsiveness of osteoclasts [17].
Glucocorticoid induced osteoporosis and hyper-
parathyroidism proceed with up regulation of RANKL
expression and inhibition of OPG secretion [17].
Immune-mediated bone diseases, presented as peri-
odontal infection or rheumatoid arthritis, are associat-
ed with up regulation of RANKL expression by acti-
vated T cells and synoviocytes [17].
In malignant diseases, such as myeloma, osteolytic
bone metastases of prostate and breast cancer, we can
observe enhanced expression of RANKL by tumor
cells and tumor-inducted increase of the RANKL/OPG
ratio in bone microenvironment. Additionally, espe-
cially in myeloma there is a sequestration and lysoso-
mal degradation of OPG by tumor cells [17]. 
Inherited skeletal diseases, like familial Paget dis-
ease and expansive skeletal hyperphosphatasia, are
caused by mutations in gene encoding the signal pep-
tide RANK. Next, juvenile Paget disease is caused by
mutation in gene encoding OPG [17]. 
Understanding the role of OPG/RANK/RANKL
system in pathogenesis of diseases stated above led to
development of new therapeutic strategies including
e.g. a monoclonal antibody to RANKL, as denosumab,
for the postmenopausal osteoporosis treatment [18].
Role of OPG/RANK/RANKL system in
immunology
A cross-talk between bone metabolism and the
immune response is called osteoimmunology. The
OPG/RANK/RANKL triad exerts activities on differ-
ent parts of immune system.
RANKL and OPG are essential for dendritic cells
functions, lymph node organogenesis, and lymphocyte
development [19]. There are many examples for
involvement this triad in immunology which comes
from experimental animal studies. OPG deficient mice
exhibit impaired thymocyte development and present-
ed disturbance in B-cell maturation and antibody
response [10]. Mice with a disrupted RANKL gene
show a lack of all lymph node organogenesis, normal
splenic and Peyer's patches organization, and also
impaired thymocyte development. RANK knock-out
mice also lacked lymph nodes and produced defective
B and T lymphocyte maturation while they exhibited
normal thymic development. It is possible that
RANKL expressed by thymic epithelial cells may be
responsible for the development and maturation of
RANK-positive lymphocytes. Moreover, RANKL
behaves as a chemotactic factor for monocytes through
its binding to membrane RANK. OPG also can modu-
late the migration of monocytes [15].
Role of OPG/RANK/RANKL system 
in vascular remodeling
Vascular calcification often occurs with advancing
age, atherosclerosis, end-stage renal disease, diabetes
mellitus and now has been suggested to be related to
ossification. It is an active process which involves
inflammatory cytokines. Many proteins responsible
for bone formation have been identified on the arterial
wall. Dendritic cells, monocytes, smooth muscle cells
are also crucial for calcium deposition in lesions
because of their capability to differentiate into
osteoblasts-like and osteoclasts-like cells [20]. Medial
calcification occurs independently of atherosclerosis
and is observed in e.g. hypervitaminosis D and ESRD.
Intimal calcification was observed almost exclusively
in atherosclerotic plaques. 
OPG and vascular remodeling
OPG seems to be basic ligand between bone tissue and
the vascular system [21]. It protects large blood ves-
sels from medial calcification. It has been shown that
the onset of arterial calcification in OPG deficient
mice can be prevented by transgenic OPG delivered
from mid gestation through adulthood. Interestingly,
postnatal intravenous injection of recombinant OPG
had no effect on the presence of vascular calcification.
It suggests that OPG cannot reverse the calcification
process once it had occurred [22]. 
Similarly, rat models showed that OPG administra-
tion prevents calcification induced by warfarin or high
doses of vitamin D but could not reverse this phenome-
non once the mineralization process had occurred [23].
OPG can also limit calcification of atherosclerotic
plaques. [24]
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Although most animal studies support a protective
role of OPG in vasculature, human studies have par-
adoxically shown a positive association between
serum OPG levels and clinical cardiovascular dis-
ease. Elevation of OPG seems to be in contrast to its
protective role upon arterial wall. For example, some
clinical reports show correlation between higher lev-
els of OPG and artery disease, vascular calcification,
advanced atherosclerosis, coronary disease, myocar-
dial infarction, heart failure, diabetic complications,
abdominal aortic aneurysm, peripheral arterial dis-
ease, symptomatic carotid artery stenosis and cardio-
vascular mortality [4,14]. Statistical analysis of
serum OPG levels in vivo has proven serum OPG as
an independent prognostic factor for cardiovascular
disease [25].
Whether elevated OPG is simply a marker of vas-
cular damage, actively mediates disease progression or
represents a mechanism aimed to limit vascular dis-
ease remind not clear [26]. OPG may act as a protec-
tive factor for vascular disease and increase in OPG
may be compensatory as a response to the progression
of vascular calcification.
RANKL and vascular remodeling
Endothelial cells and VSMCs normally produce OPG.
RANKL and RANK are not detected in normal vascu-
lature [22]. It is already known that small amount of
RANKL have been detected in initial stages of athero-
sclerosis, whereas in advanced lesions as calcified ves-
sels and valves, OPG remained constant or decreased
slightly, while the expression of RANKL and RANK
was simultaneously increased [27].
It has been shown that RANKL, which is up regu-
lated in vulnerable atherosclerotic lesions prone to
rupture, may contribute in the transition from stable to
unstable atherosclerotic plaque because of its ability to
promote monocyte/macrophage chemotaxis and
matrix degeneration [28]. Moreover, RANKL stimu-
lates osteogenic differentiation and calcification of
VSMCs [14, 16]. There are some studies that prove
association between RANKL and cardiovascular dis-
eases. In large epidemiological study of Kiechl et al.,
higher levels of RANKL significantly predicted the
risk of cardiovascular disease. This study also support
concept that RANKL contributes to the destabilization
of existed plaques [29].
The significance of OPG/RANK/RANKL axis
in nephrology
The role of OPG/RANKL/RANKL system in
chronic kidney disease complications, especially in
permanently dialysis patients, has been not fully
understood yet. Uremia induces a derangement in bone
and mineral homeostasis known as renal osteodystro-
phy. Patients with chronic kidney disease, regarding
advanced age, postmenopausal age, glucocorticoid
treatment or chronic heparin usage in HD, are at risk
for developing osteoporosis and its comorbidities.
Additionally there is a relationship between ROD and
vascular calcification [30].
OPG/RANK/RANKL system in renal 
osteodystrophy
Many humoral factors are involved in the ROD devel-
opment. The OPG/RANK/RANKL cytokine system
appears to mediate the effect of many bone turnover
factors, contributing to the pathogenesis of renal bone
disease [2]. There were conducted studies to distin-
guish different types of ROD by measuring OPG lev-
els. Coen et al. have found an inverse correlation
between serum OPG levels and histomorphometric
parameters of bone resorption what suggests, that
higher levels of serum OPG may be related to lower
bone turnover [31]. In Haas et al. study, OPG was sig-
nificantly reduced in patients on maintenance
hemodialysis (HD) therapy with high turnover disease
when compared with low turnover [32]. Whether ele-
vated serum OPG is connected with low or high bone
turnover in HD patients remind unclear and require
further investigations [33].
OPG/RANK/RANKL system in ESRD
Exposure of osteoblasts to PTH in hyperparathy-
roidism increases the expression of RANKL and
decrease the expression of OPG, thus decreased con-
centration of OPG should be expected in any type of
hyperparathyroidism. In vitro study conducted by
Huang confirmed that PTH significantly up regulates
RANKL m-RNA of bone marrow stromal osteoblasts
and inhibits OPG gene expression at all stages of
osteoblasts' differentiation [34]. 
Studies of OPG and RANKL levels in CKD and
hemodialysis patients have shown contradictory
results. OPG concentrations are reported to be higher
in HD patients [35-39], whereas RANKL level can be
higher [39,40], lower [36] or within normal range [41]
compared to healthy individuals. Kazama showed that
serum OPG levels in uremic patients were elevated
and independent of their serum PTH levels, what sug-
gested the circulating OPG to be an independent factor
affecting bone metabolism in uremic patients [42].
Avbersek-Luznik et al. study showed that serum OPG
levels were 6,4-fold higher in dialysis patients com-
pared to controls, and was depended on PTH concen-
tration [38]. Another research by Avbersek-Luznik et
al. support hypothesis that PTH increases bone resorb-
tion in HD patients through stimulating RANKL
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synthesis [40]. Conversely, in Doumouchtsis study, the
average serum concentration of sRANKL was lower in
patients on HD than in age-matched healthy controls
[36] .
In predialysis patients, serum OPG increased pro-
gressively with reduction in creatinine clearance. In
dialysis patients OPG further increased, according to
Kazama study 3-fold [43]. This concentration corre-
sponded to the OPG level that would inhibit 50% of
osteoclasts formation  in vitro [44]. Among HD
patients, serum OPG level increased significantly with
aging and with longer duration of HD. Increase in
OPG with longer duration of HD may be related to
stimulation by uremia, hemodialysis procedure itself,
and drugs [36]. Kazamo et al reported that OPG is not
removed through the polysulfon hemodialysis mem-
brane. In physiological condition, OPG monomer
seems unlikely to be eliminated through glomerular
membrane filtration because of its molecule size (60
kDa). Authors concluded that kidneys probably play a
key role not only in OPG elimination but also in its
metabolism before the renal clearance [43]. It may be
supported by finding that elevated OPG level returns
to normal after kidney transplantation [45]. 
To conclude, OPG increment might protect bone
against its intensive loss in chronically HD patients by
its accumulation in uremia and reducing of RANKL
level. This may be skeleton protective mechanism to
compensate any perturbations in bone turnover in
renal failure [36]. 
Osteoporosis in ESRD
Patient with chronic kidney disease is also at risk for
development of osteoporosis. Osteoporosis is present in
both low and high-bone turnover states and bone loss
begins much earlier in chronically HD patients than in
general population [30]. In Baretto study,
OPG/RANKL ratio in osteoporosis group was higher
and OPG as well as OPG/RANKL ratio correlated neg-
atively with trabecular bone volume (BV/TV). As men-
tioned above this could be protective mechanism that
limits the bone loss by decreasing bone resorption [30].
Doumouchtis et al. evaluated clinical and biochem-
ical correlations of bone mineral density (BMD) meas-
urements in chronic haemodialyzed patients. The high-
est OPG levels were in the lowest T-score that means
osteoporotic tertile and were higher than in osteopenic
and normal tertiles. HD patients with low BMD of
femoral neck demonstrated higher OPG levels than
patients with normal BMD [2]. This study showed that
patients on dialysis for longer period had BMD below
normal range [2].
In pathogenesis of osteoporosis in HD patients, usage
of heparin during the dialysis seems to play significant
role. Heparin is a member of glycosaminoglycan family
which shows anticoagulant activity by binding to
antithrombin thus is used for anticoagulant therapy.
One of adverse effects during heparin treatment –
reduction in bone density and development of osteo-
porosis, is related to OPG/RANKL/RANK system.
Heparin binds to OPG (C-terminal domain) and
inhibits the interaction between OPG and RANKL
thus enhances osteoclastic bone resorption [46]. Low-
molecular weight heparins (LMWHs) cause less osteo-
porosis than unfractionated heparin (UFH) [47], fol-
lows their lower inhibitory effect to OPG than standard
heparin [46].
These findings should be collated with Vic et al.
study, showing that UFH and high doses of LMWHs
increase plasma OPG concentrations. Intravenous
administration of UFH is superior to subcutaneous
injection of LMWHs in OPG mobilization into the cir-
culation. Researchers concluded that UFH has higher
affinity for OPG than LMWHs. They speculated that
UFH induces osteoporosis either by attracting OPG to
the vascular compartment or by impairing its function
in the bone microenvironment [48]. So still, further
studies are required to investigate exact role of
OPG/RANK/RANKL system in heparin-induced
osteoporosis. 
CVD risk and vascular calcifications in CKD
patients 
Patients with chronic kidney disease are at high risk
for vascular calcification because of multiple risk fac-
tors that induce transdifferentiation of VSMCs into a
chondrocyte or osteoblast-like cell. Among factors
implicating in that phenomenon are: high content of
calcium and phosphorus caused by abnormal bone
metabolism, low levels of circulating and locally pro-
duced inhibitors, impaired renal function and current
therapies [49].
Chronic kidney disease patients have two to five
times more coronary artery calcification than healthy
age-match individuals and vascular calcification is an
important prognostic marker of cardiovascular disease
in CKD patients [50]. Cardiovascular disease (CVD) is
responsible for about 50% of deaths among ESRD
patients. In chronically HD patients prevalence of
coronary artery disease is 40% [30]. Except of tradi-
tional risk factors, like hypertension, diabetes or dys-
lipidemia, there are additional factors related to uremia
and dialysis treatment, like hyperhomocysteinemia,
increased change in mineral metabolism, chronic
inflammation or oxidative stress [30]. 
In CKD patients there is a direct correlation
between vascular calcification, cardiovascular risk and
OPG level, just like in patients without chronic kidney
disease. Chronically dialyzed children with calcifica-
tion have higher OPG level than those without this
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complication [51]. Nitta et al. concluded that fast pro-
gression of vascular calcification in HD patients was
associated with higher OPG concentration [52]. In
Speer et al. study, authors showed that in HD patients
OPG is strongly related to carotid-femoral pulse wave
velocity (PWV), and that OPG related cardiovascular
risk is partly mediated by increased PWV [53].
Elevated OPG levels (especially in patients with
high CRP concentration) in Morena et al. study, pre-
dicted all-cause and cardiovascular mortality.  In the
same study,  low levels of sRANKL were associated
with a protective effect for all-cause mortality [54]
which is in accordance to Kiechl et al. study [29] but
inconsistent with Schopppet et al. [55] who have
shown, that low RANKL levels were associated with
higher vascular risk. Only Yokoyama has reported low
OPG levels as a predictor of poor prognosis in
Japanese diabetic hemodialysis patients [56].
Summary
Discovery of OPG/RANK/RANKL system was major
breakthrough in understanding of regulation of bone
remodeling. Another achievement was finding
involvement in control of immune and vascular sys-
tems. Animal studies' results are clear and dissolving
doubts about role of axis in pathogenesis of vascular
calcifications and osteoporosis. Researches in humans,
especially in CKD patients, brought many conflicting
data. We rather presume than state so several further
studies are required to elucidate exact contribution of
each OPG/RANK/RANKL molecule in development
of CKD complications. 
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